Todd Harris - Apr 3, 2023 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Signature
/s/ Ali D. Fawaz, Attorney-in-Fact
Stock symbol
TYRA
Transactions as of
Apr 3, 2023
Transactions value $
-$27,752
Form type
4
Date filed
4/5/2023, 05:20 PM
Previous filing
Mar 31, 2023
Next filing
Jun 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Options Exercise $4.5K +2K +0.12% $2.25* 1.7M Apr 3, 2023 Direct
transaction TYRA Common Stock Sale -$32.3K -2K -0.12% $16.13 1.7M Apr 3, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -2K -0.5% $0.00 398K Apr 3, 2023 Common Stock 2K $2.25 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022.
F2 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 and $16.240. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
F3 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.